MGTX: MeiraGTx Corp Analyst Target Range

Symbol and logo of brand MeiraGTx PLC (MGTX)

The asset value of MeiraGTx Holdings plc (MGTX) reflected in this chart demonstrates the dynamics of a company whose success is tied to diabetes and blindness therapies, as well as partnerships with industry behemoths, while the consensus forecast stands at 27.72. The firm minimizes external risks by producing viral vectors at its own facilities, delegating only the testing process. High engineering costs and stringent FDA regulations, combined with patents, create a significant barrier to entry for newcomers.

MGTX - MeiraGTx Holdings Consensus Target over the range 07/04/2022 - 11/16/2026

Metric breakdowns and analytics for MeiraGTx (MGTX)

- market price and analyst price targets:
General company analysis:MGTX MeiraGTx Holdings
Manufactured products of meiragtx.com

For MeiraGTx Holdings plc (MGTX), valuation depends critically on the success of gene therapies and FDA approvals. The consensus target price aggregates discounted cash flow models, eliminating time gaps between reports. This indicator measures analysts' weighted average expectation regarding fair equity value. In biotech, this trend reflects market confidence in the patentability of R&D. Target stability here serves as a marker of the balance between regulatory risks and monopoly potential.

Competitors of MeiraGTx Holdings plc

Analyst Forecast Prices TEM|Analyst Consensus Forecast QGEN (Qiagen NV)|Isis Pharmaceuticals (IONS) - Average Forecast Price|Repligen Corp - Analyst Consensus Forecast|RNA - Analyst Consensus Forecast|CRISPR Therapeutics AG (CRSP) - Price Target Chart|Broker Consensus Forecast WGS|RARE (Ultragenyx Pharmaceutical) - Analyst Consensus Forecast|Broker Consensus Forecast BEAM (Beam Tx)|Price Target Chart Sarepta (SRPT)|Twist Bioscience - Broker Consensus Forecast|Analyst Consensus Forecast TXG (10x Genomics, Inc.)|Analyst Consensus Forecast Intellia Therapeutics, Inc. NTLA|STOK - Price Target Chart|BLFS: Price Target Chart|WVE (Wave Life Sciences) - Consensus Target|Maze Therapeutics (MAZE) - Analyst Consensus Forecast|Price Target Chart Sionna Corp|Prime Medicine Inc (PRME) - Analyst Median Target|Price Target Chart Taysha Corp (TSHA)|uniQure N.V. (QURE) - Analyst Target Range|Price Target Chart REGENXBIO RGNX|SLDB: Broker Consensus Forecast|OCGN - Price Target Chart|Analyst Median Target PacBio PACB|BNTC: Analyst Consensus Forecast|Design Therapeutics - Fair Value Consensus|Price Target Chart Rocket Pharmaceuticals Inc|Consensus Target 4D Molecular Therapeutics (FDMT)|Analyst Consensus Forecast LXEO|KRRO - Average Forecast Price|Analyst Consensus Forecast EDIT (Editas Medicine, Inc.)|Silence Therapeutics Corp (SLN) - Average Forecast Price|ProQR Therapeutics N.V. - Analyst Consensus Forecast|Codexis Inc (CDXS) - Consensus Target|Sangamo Therapeutics, Inc. (SGMO) - Price Target Chart|Average Forecast Price Nautilus Biotechnology (NAUT)|MGX (Metagenomi Therapeutics) - Analyst Consensus Forecast|Average Forecast Price precisionbiosciences.com DTIL|Price Target Chart Generation Bio Co. (GBIO)|BOLD (Boundless Bio, Inc.) - Fair Value Consensus|Exicure Inc. - Consensus Target|IMNN: Broker Consensus Forecast|Phio Pharmaceuticals Corp - Analyst Consensus Forecast|Analyst Median Target Mustang Bio MBIO|RNAZ: Analyst Consensus Forecast|Bionano Genomics Inc. - Fair Value Consensus|APDN (Applied DNA Sciences Inc) - Analyst Consensus Forecast|Price Target Chart BLUE|Price Target Chart ImmunoPrecise Antibodies (IPA)|OMGA - Average Forecast Price|Singular Genomics Systems, Inc. - Consensus Target|Analyst Median Target regulusrx.com (RGLS)|SYRS - Price Target Chart|TBIO (Telesis Bio Inc.) - Broker Consensus Forecast|TRACON Pharmaceuticals, Inc (TCON) - Price Target Chart|Broker Consensus Forecast UBX